A mutation-based radiomics signature predicts response to imatinib in Gastrointestinal Stromal Tumors (GIST)

OBJECTIVES: To develop a mutation-based radiomics signature to predict response to imatinib in Gastrointestinal Stromal Tumors (GISTs). METHODS: Eighty-two patients with GIST were enrolled in this retrospective study, including 52 patients from one center that were used to develop the model, and 30...

Descripción completa

Detalles Bibliográficos
Autores principales: Cappello, Giovanni, Giannini, Valentina, Cannella, Roberto, Tabone, Emanuele, Ambrosini, Ilaria, Molea, Francesca, Damiani, Nicolò, Landolfi, Ilenia, Serra, Giovanni, Porrello, Giorgia, Gozzo, Cecilia, Incorvaia, Lorena, Badalamenti, Giuseppe, Grignani, Giovanni, Merlini, Alessandra, D’Ambrosio, Lorenzo, Bartolotta, Tommaso Vincenzo, Regge, Daniele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10362081/
https://www.ncbi.nlm.nih.gov/pubmed/37484979
http://dx.doi.org/10.1016/j.ejro.2023.100505

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10362081/
https://www.ncbi.nlm.nih.gov/pubmed/37484979
http://dx.doi.org/10.1016/j.ejro.2023.100505

Ejemplares similares